Sonova AG

Illumina is improving human health by unlocking the power of the genome. The company provides sequencing and array technologies that fuel genomic discoveries, enabling life-changing breakthroughs in cancer research, reproductive health, genetic disease understanding, and translational and consumer genomics. As a global genomics leader, Illumina innovates to make genomics more accessible to researchers, clinicians, and patients worldwide. Founded in 1998 and headquartered in San Diego, California, Illumina develops integrated systems for the analysis of genetic variation and function. The company's comprehensive portfolio spans high-throughput sequencing platforms like NovaSeq X and NextSeq systems, microarray scanners, library preparation kits, and informatics solutions including BaseSpace Sequence Hub and DRAGEN. By empowering researchers and clinicians with tools that improve cancer treatments, change disease trajectories, and protect future generations, Illumina is transforming the future of precision health and making genomics useful for all.

Horizon Surgical Systems, Inc. is a medical robotics company founded in 2021 and focused on surgical technology for ophthalmology. Its core product, Polaris™, is a surgical platform that combines AI-driven visualization with micro-robotic control, designed specifically for eye surgery. The company claims Polaris™ is the world's first AI-supported and robotics-enabled surgical platform purpose-built for ophthalmology. Horizon completed a first-in-human study involving 10 patients and, in October, announced what it describes as the world's first robotic-assisted cataract surgery - a milestone the company attributes to the Polaris™ platform. The system is designed to deliver greater precision, consistency, and safety in ophthalmic procedures. Horizon was founded by experts in ophthalmology and medical robotics and has raised $30 million in Series A funding. The company operates at the intersection of surgical robotics, AI, and microsurgery, with a stated mission to improve outcomes for patients requiring eye surgery worldwide.

We are one of the world's largest global medical technology companies, driven by a singular purpose: advancing the world of health™. For more than 125 years, we've partnered with healthcare providers on the frontlines, developing innovative technologies, services and solutions that help improve medical discovery, diagnostics and the delivery of care. With approximately 75,000 associates operating in nearly every country, we deliver billions of products annually that positively impact global healthcare. Our work is organized across three specialized business segments - Medical, Life Sciences, and Interventional - each focused on addressing significant healthcare challenges. We relentlessly commit to innovation, investing more than $1 billion annually in research and development to create breakthrough technologies that optimize clinical operations, enhance patient safety and expand access to healthcare. From introducing the first safety-engineered syringe to pioneering automated diagnostic systems, we continue to push boundaries to solve the complex challenges facing healthcare today.

Founded in 1992, Omnicell is a healthcare technology company focused on transforming how medications are managed across pharmacy settings. Its central ambition is the Autonomous Pharmacy - a model that combines automation, intelligence, and expert services to optimise clinical and business outcomes for healthcare organisations worldwide. The company's portfolio rests on four pillars: Robotics that remove human interaction from dangerous or repetitive medication management tasks Smart devices that close gaps in safety and inventory visibility Intelligent software that delivers data insights to optimise the pharmacy supply chain, including inventory management solutions Expert services designed to help customers extract maximum value from Omnicell technology Omnicell's solutions are deployed across a range of clinical environments - inpatient central pharmacies, IV rooms, points of care, outpatient specialty pharmacies, retail pharmacies, and medication adherence programmes. The company serves healthcare facilities globally; Baptist Health Alabama, for example, reported $425,000 in savings through Omnicell's intelligent inventory solutions. The company's work sits at the intersection of automation, robotics, data analytics, and pharmacy supply chain optimisation. Its stated aim is to reduce the potential for human error, streamline clinical workflows, and free clinicians to spend more time on direct patient care rather than medication management.

Maven Clinic is a virtual healthcare platform founded in 2014 and focused on women's and family health. Operating 24/7, the platform connects members with more than 30 types of specialized providers, covering fertility and family building, maternity and newborn care, parenting and pediatrics, and menopause and midlife health. Clinical, emotional, and financial support are consolidated within a single digital platform, which is available in more than 175 countries. The company has raised over $425 million in funding. Maven distributes its services primarily through employer and health plan partnerships, with more than 2,000 such partners and a total reach of 28 million lives supported. The platform is designed to integrate into existing benefits structures, positioning Maven as a specialist benefits layer for women's and family health rather than a standalone consumer product. The company grounds its clinical claims in a body of research, citing more than 40 peer-reviewed studies. Reported outcomes include up to 27% lower NICU admissions for maternity members and 30% of fertility members achieving pregnancy without assisted reproductive technology. Maven also reports meaningful improvements in maternal mental health among its members. Maven operates across several technical and clinical domains, including telemedicine infrastructure, care navigation, maternal mental health, and clinical outcomes measurement. Its scale - spanning employer benefits integration, a large multi-specialty provider network, and global reach - places it among the more established players in the digital women's health space.

CorDx is a multinational biotechnology company specialising in rapid testing and point-of-care medical device solutions for infectious diseases and other health needs. Its proprietary diagnostic products - spanning infectious disease detection (including COVID-19), pregnancy testing, drug screening, and biomarker detection - hold CE Marks and approvals from regulatory bodies including the FDA, serving both healthcare providers and consumers. The company employs more than 2,100 people and maintains manufacturing operations in the United States as well as internationally. The company operates across more than 100 countries and, through the broader CorDx Union ecosystem, claims a reach extending to over a billion users in 170+ countries. Its supply chain is vertically integrated, with strategic manufacturing footprints designed to support global distribution at scale. CorDx positions its work at the intersection of diagnostics, artificial intelligence, and data science, with active research and development underpinning its product portfolio. The company's stated focus is on expanding access to reliable, rapid diagnostics across both clinical and consumer health settings worldwide.